Skip to main content
    K

    Krystal Biotech Inc (KRYS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $297.90
    -7.33 (-2.40%)

    Market Cap: $9.05B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Krystal Biotech Inc (KRYS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 2, 2026. Financial statements from company filings, amounts in US dollars.

    Krystal Biotech reported revenue of $389.13M for the fiscal year ended Dec 31, 2025, up 33.9% from the year before. That year, net income was $204.83M with a net margin of 52.6%, operating cash flow was $200.87M and free cash flow was $188.91M. The quarter ended Sep 30, 2026 had revenue of $127.34M and net income of $63.07M.

    Revenue and Margins

    The operating margin was 41.5% in the fiscal year ended Dec 2025.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$389.13M+33.9%94.1%41.5%52.6%
    Dec 2024$290.51M+473.0%93.1%22.6%30.7%
    Dec 2023$50.70MN/A93.9%-216.2%21.6%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 129.7% from the year before. In the quarter ended Sep 2026, net income fell 20.5% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$389.13M$290.51M$50.70M$0$0$0$0$0$0$0
    Cost of revenue$23.05M$20.06M$3.09M$0$0$0$0$0$0$0
    Gross profit$366.08M$270.45M$47.60M$0$0$0$0$0$0$0
    Research and development$58.05M$53.58M$46.43M$42.46M$27.88M$17.94M$15.62M$7.76M$3.21M$741.00K
    Operating income$161.29M$65.75M-$109.62M-$145.20M-$68.28M-$33.00M-$22.08M-$11.92M-$4.77M-$1.14M
    Net income$204.83M$89.16M$10.93M-$139.97M-$69.57M-$32.17M-$19.09M-$10.89M-$7.92M-$1.15M
    EBITDA$167.85M$72.46M-$3.71M-$141.81M-$65.51M-$30.32M-$20.99M-$10.75MN/AN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$127.34M$119.22M$116.36M$107.11M$97.80M$96.04M$88.18M$91.14M$83.84M$70.28M$45.25M$42.14M
    Gross profit$119.78M$112.78M$110.03M$100.51M$93.54M$88.88M$83.16M$86.19M$77.16M$64.28M$42.83M$39.05M
    Operating income$71.14M$58.42M$53.69M$44.44M$41.37M$39.40M$36.25M$41.39M$22.47M$8.57M-$6.68M$3.25M
    Net income$63.07M$54.77M$55.93M$51.40M$79.36M$38.33M$35.73M$45.48M$27.18M$15.57M$932.00K$8.69M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.77M by $494.53M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.33B$1.06B$818.36M$558.45M$626.29M$310.84M$209.02M$116.12M$50.11M$2.18M
    Current assets$1.02B$742.04M$587.91M$383.78M$442.27M$275.06M$195.88M$112.65M$49.91M$2.17M
    Cash and equivalents$496.30M$344.87M$358.33M$161.90M$341.25M$268.27M$187.51M$103.67M$49.59M$1.92M
    Total liabilities$114.23M$109.46M$39.71M$36.22M$32.72M$18.76M$6.11M$2.89M$640.00K$1.89M
    Short-term debt$1.77M$1.22M$1.47M$1.56M$1.04M$8.24M$480.00KN/AN/A$0
    Long-term debtN/AN/AN/AN/AN/AN/AN/AN/A$0$1.84M
    Shareholder equity$1.22B$946.38M$778.64M$522.23M$593.58M$292.08M$202.91M$113.23M$49.47M$289.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.59B$1.50B$1.40B$1.33B$1.24B$1.14B$1.07B$1.06B$982.32M$917.66M$853.30M$818.36M
    Total liabilities$150.47M$141.52M$120.24M$114.23M$102.22M$97.75M$89.74M$109.46M$96.47M$78.77M$54.05M$39.71M
    Cash and equivalents$462.84M$427.74M$501.31M$496.30M$392.60M$353.83M$308.77M$344.87M$373.97M$345.79M$359.01M$358.33M
    Shareholder equity$1.44B$1.36B$1.28B$1.22B$1.14B$1.04B$984.67M$946.38M$885.85M$838.89M$799.24M$778.64M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 94.0% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$200.87M$123.42M-$88.80M-$100.57M-$47.94M-$26.08M-$18.69M-$9.45M-$3.89M-$1.31M
    Capital expenditures$11.95M$4.24M$11.80M$52.98M$68.34M$14.84M$6.40M$2.23M$210.00K$15.00K
    Free cash flow$188.91M$119.18M-$100.60M-$153.55M-$116.27M-$40.93M-$25.09M-$11.68M-$4.10M-$1.33M
    Investing cash flow-$58.42M-$163.44M$82.64M-$114.08M-$226.77M-$11.18M-$4.99M-$10.32M-$210.00K-$15.00K
    Financing cash flow$8.71M$27.01M$202.75M$35.35M$347.69M$118.02M$107.53M$73.85M$51.77M$3.25M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$91.25M$74.79M$80.38M$77.51M$39.66M$52.73M$30.97M$52.84M$58.86M-$4.17M$15.89M-$7.23M
    Capital expenditures$996.00K$3.56M$7.15M$2.14M$1.70M$1.90M$6.20M$801.00K$1.05M$1.13M$1.26M$1.85M
    Free cash flow$90.25M$71.22M$73.23M$75.37M$37.95M$50.83M$24.77M$52.04M$57.81M-$5.30M$14.63M-$9.08M
    Last 12 quarters

    Frequently Asked Questions About KRYS

    What is Krystal Biotech's annual revenue?

    Krystal Biotech reported revenue of $389.13M for the fiscal year ended Dec 31, 2025.

    How fast is Krystal Biotech's revenue growing?

    Revenue was up 33.9% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Krystal Biotech profitable?

    Yes. Krystal Biotech reported net income of $204.83M for the fiscal year ended Dec 31, 2025, with a net margin of 52.6%.

    How much free cash flow does KRYS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $200.87M minus capital expenditures of $11.95M produced free cash flow of $188.91M.

    How much debt does Krystal Biotech have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.77M and cash and equivalents of $496.30M.